Common heart drug could buy time for risky pregnancies
NCT ID NCT07098975
Summary
This study is testing whether a daily dose of a common cholesterol-lowering drug, pravastatin, can help prolong pregnancy in women diagnosed with severe preeclampsia or poor fetal growth between 24 and 30 weeks. The goal is to safely delay delivery, reducing the serious health risks associated with extreme prematurity for the baby. Researchers will compare outcomes between women receiving the real medication and those receiving a placebo pill, and will also check the heart health of mothers and babies six months after birth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLACENTAL INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clínic de Barcelona
NOT_YET_RECRUITINGBarcelona, Spain
-
Hospital de la Santa Creu i de Sant Pau
RECRUITINGBarcelona, 08025, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.